Interactions between thioridazine and bromocriptine in a patient with a prolactin-secreting pituitary adenoma

Richard J. Robbins; Philip A. Kern; Troy L. Thompson

doi:10.1016/0002-9343(84)91010-6

Interactions between thioridazine and bromocriptine in a patient with a prolactin-secreting pituitary adenoma

Richard J. Robbins, Philip A. Kern, Troy L. Thompson

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Reported herein is the possible interaction between two drugs used to treat a man with a large prolactin-secreting pituitary adenoma. The patient had a long history of schizophrenia that was treated with many different medications, including phenothlazines. Evaluation of progressive lethargy led to the discovery of a large parasellar tumor and a prolactin level of 7,981 ng/ml. His serum prolactln level fell to the 400 ng/ml range during bromocriptine therapy but rose whenever the antipsychotic thioridazine was added to his regimen. A marked deterioration of his visual fields was noted after 3 months' therapy with both drugs, and this abnormality resolved five days after the thioridazine was stopped. The use of dopamlne antagonists such as thioridazine in patients with prolactinoma may interfere with bromocriptine's action, resulting in potentially serious complications.

Original language	English
Pages (from-to)	921-923
Number of pages	3
Journal	American Journal of Medicine
Volume	76
Issue number	5
DOIs	https://doi.org/10.1016/0002-9343(84)91010-6
State	Published - May 1984

Bibliographical note

Funding Information:
From the Division of Endocrinology and Psychiatric Liaison Division, Departments of Medicine and Psychiatry, University of Colorado Health Sciences Center, Denver, Colorado. This work was supported in part by Sandoz, Inc., East Hanover, New Jersey. Requests for reprints should be addressed to Dr. Richard J. Robbins, Endocrine Division, 6151, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, Colorado 80262. Manuscript accepted June 14, 1983.

Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/0002-9343(84)91010-6

Cite this

@article{8220d9ca301048799256bacfc177e079,

title = "Interactions between thioridazine and bromocriptine in a patient with a prolactin-secreting pituitary adenoma",

abstract = "Reported herein is the possible interaction between two drugs used to treat a man with a large prolactin-secreting pituitary adenoma. The patient had a long history of schizophrenia that was treated with many different medications, including phenothlazines. Evaluation of progressive lethargy led to the discovery of a large parasellar tumor and a prolactin level of 7,981 ng/ml. His serum prolactln level fell to the 400 ng/ml range during bromocriptine therapy but rose whenever the antipsychotic thioridazine was added to his regimen. A marked deterioration of his visual fields was noted after 3 months' therapy with both drugs, and this abnormality resolved five days after the thioridazine was stopped. The use of dopamlne antagonists such as thioridazine in patients with prolactinoma may interfere with bromocriptine's action, resulting in potentially serious complications.",

author = "Robbins, {Richard J.} and Kern, {Philip A.} and Thompson, {Troy L.}",

note = "Funding Information: From the Division of Endocrinology and Psychiatric Liaison Division, Departments of Medicine and Psychiatry, University of Colorado Health Sciences Center, Denver, Colorado. This work was supported in part by Sandoz, Inc., East Hanover, New Jersey. Requests for reprints should be addressed to Dr. Richard J. Robbins, Endocrine Division, 6151, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, Colorado 80262. Manuscript accepted June 14, 1983. Copyright: Copyright 2014 Elsevier B.V., All rights reserved.",

year = "1984",

month = may,

doi = "10.1016/0002-9343(84)91010-6",

language = "English",

volume = "76",

pages = "921--923",

number = "5",

}

TY - JOUR

T1 - Interactions between thioridazine and bromocriptine in a patient with a prolactin-secreting pituitary adenoma

AU - Robbins, Richard J.

AU - Kern, Philip A.

AU - Thompson, Troy L.

N1 - Funding Information: From the Division of Endocrinology and Psychiatric Liaison Division, Departments of Medicine and Psychiatry, University of Colorado Health Sciences Center, Denver, Colorado. This work was supported in part by Sandoz, Inc., East Hanover, New Jersey. Requests for reprints should be addressed to Dr. Richard J. Robbins, Endocrine Division, 6151, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, Colorado 80262. Manuscript accepted June 14, 1983. Copyright: Copyright 2014 Elsevier B.V., All rights reserved.

PY - 1984/5

Y1 - 1984/5

N2 - Reported herein is the possible interaction between two drugs used to treat a man with a large prolactin-secreting pituitary adenoma. The patient had a long history of schizophrenia that was treated with many different medications, including phenothlazines. Evaluation of progressive lethargy led to the discovery of a large parasellar tumor and a prolactin level of 7,981 ng/ml. His serum prolactln level fell to the 400 ng/ml range during bromocriptine therapy but rose whenever the antipsychotic thioridazine was added to his regimen. A marked deterioration of his visual fields was noted after 3 months' therapy with both drugs, and this abnormality resolved five days after the thioridazine was stopped. The use of dopamlne antagonists such as thioridazine in patients with prolactinoma may interfere with bromocriptine's action, resulting in potentially serious complications.

AB - Reported herein is the possible interaction between two drugs used to treat a man with a large prolactin-secreting pituitary adenoma. The patient had a long history of schizophrenia that was treated with many different medications, including phenothlazines. Evaluation of progressive lethargy led to the discovery of a large parasellar tumor and a prolactin level of 7,981 ng/ml. His serum prolactln level fell to the 400 ng/ml range during bromocriptine therapy but rose whenever the antipsychotic thioridazine was added to his regimen. A marked deterioration of his visual fields was noted after 3 months' therapy with both drugs, and this abnormality resolved five days after the thioridazine was stopped. The use of dopamlne antagonists such as thioridazine in patients with prolactinoma may interfere with bromocriptine's action, resulting in potentially serious complications.

UR - http://www.scopus.com/inward/record.url?scp=0021338472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021338472&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(84)91010-6

DO - 10.1016/0002-9343(84)91010-6

M3 - Article

C2 - 6720732

AN - SCOPUS:0021338472

SN - 0002-9343

VL - 76

SP - 921

EP - 923

JO - American Journal of Medicine

JF - American Journal of Medicine

IS - 5

ER -

Interactions between thioridazine and bromocriptine in a patient with a prolactin-secreting pituitary adenoma

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this